Table 4.
EC50 values of different PDE-subtype inhibitors with and without Fs.Cr pretreatment.
| PDE inhibitor | ||||
| Cilostazol (µM) | Control | +Fs.Cr | +Rolipram | +Zaprinast |
| EC50 | 156.3# | 0.91∗∗∗ | 0.15∗∗∗ | 2.83∗∗∗ |
| CI | 76.32 to 319.9 | 0.35 to 2.35 | 0.06 to 0.39 | 1.48 to 5.41 |
| Rolipram (µM) | Control | +Fs.Cr | +Cilostazol (µM) | +Zaprinast |
| EC50 | 12.41# | 10.34 | 2.421∗∗∗ | 1.61∗∗∗ |
| CI | 6.42 to 23.98 | 5.49 to 19.46 | 1.21 to 4.83 | 0.96 to 2.70 |
| Zaprinast (µM) | Control | +Fs.Cr | +Rolipram | +Cilostazol |
| EC50 | 146.3# | 3.59∗∗∗ | 19.28∗∗∗ | 0.38∗∗ |
| CI | 74.45 to 287.4 | 1.381 to 9.37 | 11.91 to 31.21 | 0.15 to 0.96 |
EC50: effective concentration to produce 50% response; CI: confidence interval; Fs.Cr: aqueous-methanolic crude extract of Flaxseed (70; 30). All concentrations are in µM. ∗∗∗p < 0.001; ∗∗p < 0.01; one-way ANOVA was done followed by Tukey's posttest to compare the significance of means ± SEM of controls with other groups. #All treatment groups are compared with Control.